Friday, July 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 10 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 12109196

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  2. US 12109230

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  3. US 12109225

    Methods for potentiating cancer treatment using ionizing radiation

    GLYCOMIRA THERAPEUTICS, INC. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  4. US 12109231

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  5. US 12109229

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  6. US 12109272

    Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers

    Corcept Therapeutics Incorporated · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  7. US 12109228

    Treatment of neurodegenerative disease with sodium chlorite

    The Regents of the University of California · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  8. US 12109201

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  9. PT 3721882

    TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Oct 4, 2024 · Expires Sep 29, 2044

    granted
  10. US 12104163

    Adeno-associated virus vectors for treatment of Rett syndrome

    Sarepta Therapeutics, Inc. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  11. US 12102646

    Compositions for the treatment of fibrosis and inflammation

    Viking Therapeutics, Inc. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  12. US 12102642

    Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  13. US 12102640

    Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  14. US 12097198

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  15. US 12098118

    Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction

    Regents of the University of Minnesota · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  16. US 12097213

    Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy

    The Board of Regents of the University of Texas System · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  17. US 12097188

    Compositions and methods for the treatment of macular degeneration

    Aldeyra Therapeutics, Inc. · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  18. US 12091397

    Dihydroquinolinones for medical treatment

    C4 THERAPEUTICS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  19. US 12090140

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  20. US 12090142

    Combination therapy for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  21. US 12084473

    β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  22. US 12083184

    Hydrogel prodrug for treatment

    Viking Scientific, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  23. US 12083192

    Methods for treatment of patients with myelodysplastic syndromes

    Actinium Phamaceuticals, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  24. US 12083141

    Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted